← Scoopfeeds — Intelligent news, curated.
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18
business

Stifel reiterates Buy rating on Trevi Therapeutics stock at $18

Investing.com · May 6, 2026, 5:39 AM · Also reported by 1 other source

Stifel reiterates Buy rating on Trevi Therapeutics stock at $18

Read full story on Investing.com → More top stories

Also covered by

Yahoo Finance Hinge Health Stock Sees RS Rating Jump Ahead Of Earnings

More in business

Investing.com
Earnings call transcript: Comcast beats EPS forecast, stock dips Q1 2026
Investing.com
Bitcoin steady above $81k, trims some gains after Strategy flags potential sales
Investing.com
One Health Group appoints Joe Hopwood as commercial manager
Investing.com
Infineon raises FY26 outlook as AI chip surge offsets EV slump
Investing.com
Earnings call transcript: Kongsberg Gruppen Q1 2026 misses EPS forecast, stock stable
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop